{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:02:35Z","timestamp":1789437755627,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009736","name":"BioVersys AG, Basel, Switzerland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>BV100 is a novel intravenous (IV) formulation of rifabutin under development for the treatment of serious Acinetobacter baumannii infections. The primary objectives of these studies were to assess potential pharmacokinetic interactions between BV100 and two index cytochrome P450 3A enzymes (CYP3A) probes, midazolam (substrate) and itraconazole (inhibitor), and to evaluate BV100\u2019s safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two open-label Phase 1 studies were conducted in healthy participants. Study 1 evaluated the impact of multiple IV doses of BV100 (300\u2005mg) on the pharmacokinetics of a single oral dose of midazolam (5\u2005mg). Study 2 assessed the impact of repeated oral doses of itraconazole (200\u2005mg) on the pharmacokinetics of a single IV dose of BV100 (300\u2005mg). Pharmacokinetic parameters [maximum plasma concentration (Cmax), area under the plasma concentration\u2013time curve from zero to 24 hours (AUC0\u201324), area under the plasma concentration\u2013time curve from zero to infinity (AUC0\u2013\u221e)] were analysed using geometric means and 90% confidence intervals (CI). Drug\u2013drug interactions (DDIs) were defined as a 90% CI outside the equivalence range of 80%\u2013125%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both studies demonstrated DDIs. BV100 increased midazolam metabolism, with Cmax and AUC test\/reference ratios of 77% and 53%, respectively. The decreased midazolam AUC (47%) indicated BV100 is a mild\/weak CYP3A inducer by EMA\/FDA criteria. Itraconazole decreased BV100 metabolism, resulting in increased BV100 exposure (Cmax 1.1-fold; AUC 1.3-1.7-fold), consistent with mild inhibition. BV100 was considered generally safe and well tolerated in both studies, with no serious adverse events reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BV100 is a mild\/weak CYP3A enzyme inducer and a mild substrate for CYP3A inhibitors. However, co-administration with strong CYP3A inhibitors resulted in a disproportionate increase in exposure to the active metabolite 25-O-desacetyl rifabutin, leading to an \u223c2-fold increase in total active-moiety exposure. Clinical monitoring is advised when BV100 is co-administered with a strong CYP3A inhibitor. BV100 was safe and well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag317","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:14:59Z","timestamp":1788520499000},"source":"Crossref","is-referenced-by-count":0,"title":["BV100 (rifabutin IV) drug interaction studies in healthy subjects with index CYP450 3A probes midazolam and itraconazole"],"prefix":"10.1093","volume":"81","author":[{"given":"Pierre","family":"Delique","sequence":"first","affiliation":[{"name":"BioVersys SAS , C\/o Institut Pasteur de Lille, 1 rue du Professeur Calmette, Lille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kemmer","sequence":"additional","affiliation":[{"name":"BioVersys AG , C\/o Technologiepark Basel, Hochbergerstrasse 60c, Basel CH-4057 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Husband","sequence":"additional","affiliation":[{"name":"BioVersys SAS , C\/o Institut Pasteur de Lille, 1 rue du Professeur Calmette, Lille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9za","family":"Lakner","sequence":"additional","affiliation":[{"name":"CRU Hungary Kft. , G\u00f6d H-2131 ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"BioVersys AG , C\/o Technologiepark Basel, Hochbergerstrasse 60c, Basel CH-4057 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Jung","sequence":"additional","affiliation":[{"name":"BioVersys AG , C\/o Technologiepark Basel, Hochbergerstrasse 60c, Basel CH-4057 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F","family":"Shorr","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, Medstar Washington Hospital Center , 110 Irving St., NW, Washington, DC 20010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn E","family":"Dale","sequence":"additional","affiliation":[{"name":"BioVersys SAS , C\/o Institut Pasteur de Lille, 1 rue du Professeur Calmette, Lille ,","place":["France"]},{"name":"BioVersys AG , C\/o Technologiepark Basel, Hochbergerstrasse 60c, Basel CH-4057 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"2026091421115990200_dkag317-B1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12879-021-07024-4","article-title":"Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019","volume":"22","author":"Pogue","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2026091421115990200_dkag317-B2","volume-title":"Bacterial Priority Pathogens List 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance","author":"World Health Organization","year":"2024"},{"key":"2026091421115990200_dkag317-B3","volume-title":"Antibiotic Resistance Threats in the United States, 2019","author":"CDC","year":"2019"},{"key":"2026091421115990200_dkag317-B4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026091421115990200_dkag317-B5","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/j.drudis.2021.07.001","article-title":"Rifabutin for infusion (BV100) for treatment of severe carbapenem-resistant Acinetobacter baumannii infections","volume":"26","author":"Trebosc","year":"2021","journal-title":"Drug Discov Today"},{"key":"2026091421115990200_dkag317-B6","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41564-020-0737-6","article-title":"A nutrient-limited screen unmasks rifabutin hyperactivity for XDR Acinetobacter baumannii","volume":"5","author":"Luna","year":"2020","journal-title":"Nat Microbiol"},{"key":"2026091421115990200_dkag317-B7","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1093\/jac\/dkaa370","article-title":"In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms","volume":"75","author":"Trebosc","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026091421115990200_dkag317-B8","volume-title":"Thirty-First European Congress of Clinical Microbiology and Infectious Diseases, Online Meeting","author":"Trebosc","year":"2021"},{"key":"2026091421115990200_dkag317-B9","doi-asserted-by":"publisher","first-page":"e02204-20","DOI":"10.1128\/AAC.02204-20","article-title":"Synergistic rifabutin and colistin reduce emergence of resistance when treating Acinetobacter baumannii","volume":"65","author":"Cheng","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091421115990200_dkag317-B10","volume-title":"Thirty-First European Congress of Clinical Microbiology and Infectious Diseases, Online meeting","author":"Dale"},{"key":"2026091421115990200_dkag317-B11","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1128\/AAC.33.8.1237","article-title":"Pharmacokinetics of rifabutin","volume":"33","author":"Skinner","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091421115990200_dkag317-B12","doi-asserted-by":"publisher","first-page":"ofaa460","DOI":"10.1093\/ofid\/ofaa460","article-title":"Pharmacology, dosing, and side effects of rifabutin as a possible therapy for antibiotic-resistant Acinetobacter infections","volume":"7","author":"Phillips","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026091421115990200_dkag317-B13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2026091421115990200_dkag317-B14","doi-asserted-by":"publisher","first-page":"e01582-25","DOI":"10.1128\/aac.01582-25","article-title":"Single- and multiple-ascending dose study of the pharmacokinetics, safety and tolerability of BV100 (rifabutin for infusion) in healthy volunteers","volume":"70","author":"Kemmer","year":"2026","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091421115990200_dkag317-B15","author":"U.S.Food and Drug Administration"},{"key":"2026091421115990200_dkag317-B16","author":"European Medicines Agency"},{"key":"2026091421115990200_dkag317-B17","volume-title":"Thirty-First European Congress of Clinical Microbiology and Infectious Diseases, Online Meeting","author":"Mueller","year":"2021"},{"key":"2026091421115990200_dkag317-B18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/BF00615223","article-title":"Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects","volume":"34","author":"Perucca","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"2026091421115990200_dkag317-B19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0009-2797(99)00089-7","article-title":"Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes","volume":"121","author":"Reinach","year":"1999","journal-title":"Chem Biol Interact"},{"key":"2026091421115990200_dkag317-B20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0009-2797(97)00071-9","article-title":"Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics evaluation of rifampin, rifapentine, and rifabutin","volume":"107","author":"Li","year":"1997","journal-title":"Chem Biol Interact"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/10\/dkag317\/71078597\/dkag317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/10\/dkag317\/71078597\/dkag317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:12:03Z","timestamp":1789434723000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag317\/8794375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag317","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"dkag317"}}